Phathom Pharmaceuticals I... (PHAT)
NASDAQ: PHAT
· Real-Time Price · USD
10.69
0.22 (2.10%)
At close: Aug 15, 2025, 12:43 PM
2.10% (1D)
| Bid | 10.67 |
| Market Cap | 758.39M |
| Revenue (ttm) | 114.04M |
| Net Income (ttm) | -330.15M |
| EPS (ttm) | -4.67 |
| PE Ratio (ttm) | -2.29 |
| Forward PE | -23.01 |
| Analyst | Buy |
| Ask | 10.69 |
| Volume | 361,797 |
| Avg. Volume (20D) | 2,319,162 |
| Open | 10.56 |
| Previous Close | 10.47 |
| Day's Range | 10.46 - 10.85 |
| 52-Week Range | 2.21 - 19.71 |
| Beta | 0.45 |
About PHAT
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol PHAT
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for PHAT stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsEarnings Surprise
Phathom Pharmaceuticals has released their quartely earnings
on Aug 7, 2025:
Next Earnings Release
Phathom Pharmaceuticals Inc. is scheduled to release its earnings on
Nov 6, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
2 months ago
+90.19%
Phathom Pharmaceuticals shares are trading higher ...
Unlock content with
Pro Subscription
3 months ago
-17.86%
Phathom Pharmaceuticals shares are trading lower after HC Wainwright maintained a Buy rating on the stock and lowered its price target from $28 to $20.
2 months ago · seekingalpha.com
Tiny Phathom Pharmaceuticals Just An Got FDA Blessing And Big-Time Upside: BuyI'm bullish on Phathom Pharmaceuticals, Inc. after the FDA granted 10-year exclusivity to their flagship GI drug, Voquezna, giving them near-monopoly status. For those who don't know, this is a big de...
2 months ago · https://thefly.com
Phathom Pharmaceuticals price target raised by $6 at Cantor Fitzgerald, here's why19 Aug